Neoadjuvant therapy is a preoperative systemic treatment for patients with breast cancer.This therapy has greatly improved the clinical outcomes of human epidermal growth factor receptor 2(HER2)-positive breast cancer,which is associated with poor prognosis.Currently,dual anti-HER2 antibodies,including trastuzumab and pertuzumab,combined with non-anthracycline chemotherapy is one of the standard regimens to achieve high pathologic complete response rate and satisfactory efficacy.The combination of trastuzumab with tyrosine kinase inhibitors,antibody-drug conjugate drugs,or immunotherapy combined with target therapy,under the indications of reasonable biomarkers,is effective for HER2-positive breast cancer.In this article,we briefly reviewed neoadjuvant therapy in the dual-targeting therapy era and discussed its future perspectives.
关键词
HER2阳性乳腺癌/新辅助治疗/pCR/曲妥珠单抗/帕妥珠单抗
Key words
HER2-positive breast cancer/Neoadjuvant therapy/pCR/Trastuzumab/Pertuzumab
维普
万方数据